Fig. 2: [¹⁸F]FSPG retention is altered following pharmacological and genetic manipulation of NRF2.

a Chemical structure of KI696. b Representative western blot of NRF2 and xCT expression in NRF2-low cell lines 24 h post treatment with vehicle control or 200 µM KI696. Actin was used as a loading control. c–f Analysis of cystine (Cys₂) consumption (c), intracellular glutamate (d) and intracellular GSH (e) in NRF2-low lines following KI696 treatment compared to vehicle control. f Intracellular [¹⁸F]FSPG retention in NRF2-low cells after KI696 treatment compared to vehicle control. g Representative western blot of NRF2 and xCT expression in NSCLC cells following genetic manipulation of NRF2. Intracellular GSH (h, j) and [¹⁸F]FSPG retention (i, k) in genetically modified NSCLC cells. Data are presented as mean ± SD from n = 3–4 independent experiments. Comparisons were made using an unpaired two-tailed Student’s t-test (d–e, j–k), an unpaired one-tailed Student’s t-test (f), or a one-way ANOVA followed by correction for multiple comparisons via the Tukey method (h–i). For (b–k), source data are provided as a Source Data file.